CDSCO Grants Marketing Authorization for Qfitlia to Prevent Bleeding in Haemophilia Patients

Exam-focused facts from the 22 October 2026 current affairs briefing.

Key facts

Sanofi Healthcare received marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) for Qfitlia, a therapy used to prevent bleeding in haemophilia patients.
The CDSCO approval covers adults and adolescents aged 12 years and older, applicable to patients with or without factor VIII or IX inhibitors.
Qfitlia (Fitusiran) is a therapy used for routine prophylaxis to prevent or reduce bleeding episodes in patients with Haemophilia A or B.
The approval was based on data derived from the ATLAS phase 3 clinical development programme.